SLC5A2 and diabetic ketoacidosis: Diabetic ketoacidosis is a serious complication associated with the use of SGLT2 inhibitors in both humans and cats [6, 7, 8, 33, 34], with ~75% of suspected cases occurring within the first 2 weeks of treatment with velagliflozin in cats [6, 7].